News
MTIP is pleased to announce the successful completion of Oviva’s €200m Series D financing round comprising a mix of primary and secondary capital.
MTIP is pleased to announce the successful completion of Oviva’s €200m Series D financing round comprising a mix of primary and secondary capital.
MTIP is pleased to announce the successful completion of Oviva’s €200m Series D financing round comprising a mix of primary and secondary capital. Oviva, Europe’s leading provider of digital, reimbursed care for weight-related and chronic conditions, grew significantly over the course of our investment so far. MTIP actively supported the company in building robust operational structures and scaling its presence across Europe and will continue to support Oviva’s next phase of growth.
Since MTIP’s initial investment, Oviva has expanded rapidly, delivering strong revenue growth and treating more than 1 million patients to date. The company’s programs are now fully reimbursed in three countries, have achieved sustained year-over-year growth, and reached positive cash flow. AI-driven capabilities support scalable, high-quality care delivery for patients and clinicians, while also strengthening the economic sustainability of the model, reinforcing Oviva’s leadership as Europe’s foremost virtual clinic for chronic care.
“This development reflects the strong progress Oviva has made throughout our partnership, said Dr. Christoph Kausch, Managing Partner at MTIP. “We worked closely with Oviva’s leadership – acting as a sparring partner in building commercial foundations, enhancing product capabilities, and preparing the organization for long-term success. Our belief in the company’s trajectory remains strong, which is why we are looking forward to continuing our support for the team.”
“Oviva’s mission is to help people with chronic conditions live healthier lives through accessible, personalized digital care,” said Kai Eberhardt, CEO of Oviva. “With new investors joining us – and continued commitment from MTIP – we will accelerate our expansion, scale our care pathways, and continue delivering high-quality outcomes to patients across Europe. We are extremely proud of the progress to date and excited for what comes next.”
For MTIP, the transaction underscores our dedication to supporting high-growth healthcare software companies that transform care delivery. Retaining a minority position ensures continued alignment with Oviva’s long-term ambition and future value creation.
About Oviva
Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva is Europe’s leading provider of digital, reimbursed care for weight-related and chronic conditions. Its AI-enabled platform combines a medical-device-certified app with multidisciplinary clinical teams to deliver personalized, evidence-based therapy at scale.
Oviva works closely with public health systems, insurers and clinicians. Its programs are reimbursed across all core markets: As a certified Digital Health Application (DiGA) in Germany, in partnership with the NHS in the UK, and as an integrated part of the Swiss healthcare system.
Oviva’s approach is clinically validated, outcome-driven and designed to reduce the burden on healthcare professionals while improving access, quality and efficiency of care. In 2026, Oviva expanded its platform to include hypertension management, further strengthening its role as a comprehensive digital chronic care provider.
For more information, visit: www.oviva.com
About MTIP
MTIP is a Swiss growth and buyout PE firm acquiring and investing in high-growth, profitable European healthcare software companies. We partner with founders and visionary management teams to scale businesses that drive innovation and impact in the healthcare sector, thereby creating long-term value for patients, providers, and society.
For more information, visit www.mtip.ch.
Media Contact:
Anja-Vanessa Peter
Investor Relations & Communication Manager
.svg)
.svg)
.png)
